Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study

BACKGROUND: Data supporting the routine use of adjuvant chemotherapy (AC) compared with no AC (noAC) following neoadjuvant chemotherapy (NAC) and resection for pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to determine whether AC improves long-term survival in patients receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamarajah, Sivesh K., White, Steven A., Naffouje, Samer A., Salti, George I, Dahdaleh, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Hepatobiliary Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460503/
https://www.ncbi.nlm.nih.gov/pubmed/33786676
http://dx.doi.org/10.1245/s10434-021-09823-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460503/
https://www.ncbi.nlm.nih.gov/pubmed/33786676
http://dx.doi.org/10.1245/s10434-021-09823-0

Ejemplares similares